Osteoarthritis is a common disease which affects at least one in every three people over 35 years of age irrespective of ethnic origin.' Many of those affected use non-steroidal anti-inflammatory drugs (NSAIDs) for symptomatic relief. As osteoarthritis is characterised by progressive resorption of the articular cartilage it is pertinent to consider the effects of NSAIDs on cartilage metabolism. The in vitro effects of NSAIDs on cartilage have been studied in isolated chondrocytes, cartilage explants, and in animals with and without induced arthritis.2" The results have varied, but in several systems negative effects on proteoglycan synthesis have been observed. [2] [3] [4] [5] [6] Piroxicam is a widely used NSAID which has been shown to reduce the incidence of osteoarthritic lesions in genetically susceptible C57 black mice.7 In rats and dogs piroxicam does not affect proteoglycan synthesis in vitro.
Whether it affects proteoglycan catabolism in animals or humans is still unclear; however, the findings of Verbruggen et al suggest that it may retard the release of proteoglycans from human cartilage matrix. 8 The purpose of this study was to examine the effect of piroxicam on the release of proteoglycans from articular cartilage in patients with osteoarthritis of the knee joint.
Patients and methods PATIENT SELECTION Patients were selected for study if were added to 140 pt of 0-02 mol/l TRIS-HCI (pH 8-0) and thoroughly mixed to ensure dispersion of the synovial fluid into the buffer. To this diluted synovial fluid was added 20 tl of 0-02 mol/l TRIS-HCI buffer (pH 8 0) containing 5 U/ml chondroitin ABC lyase. The tubes were then gently mixed and incubated for four hours at 37°C.
Preliminary studies showed that when synovial fluids are digested under these conditions keratan sulphate is the only remaining sulphated glycosaminoglycan. After digestion with chondroitin ABC lyase 100 pA aliquots of the digest were transferred to fresh tubes and mixed with an equal volume of 0-02 mol/l TRIS-HCI buffer (pH 7-00) containing 0-004 mol/l N-acetyl cysteine and 0 13 units of papain. All samples were then mixed and incubated for two hours at 65°C. On completion of this digestion the papain was inactivated and the ionic strength of the solution adjusted as described previously. Aliquots (40 pt) of the final digest were then transferred to the wells of a microtitre plate and mixed with 250 R1 of dimethylmethylene blue dye. The dimethylmethylene blue reagent was prepared by adding 3 04 g glycine, 2-37 g NaCl, and 16 mg 1,9-dimethylmethylene blue to 1 litre of doubly distilled water. The pH was adjusted to 3-0 with HC1 and the reagent was stored in a light shielded bottle. Absorbances were read at 540 nm. The assay was calibrated with keratan sulphate from bovine cornea. Control samples of purified chondroitin sulphate and keratan sulphate diluted in phosphate buffered physiological saline containing bovine serum albumin (40 mg/l) were processed in the same way as biological samples to monitor the efficacy of the chondroitin sulphate elimination and to ensure that the keratan sulphate concentrations were not affected by the assay procedure. Amounts of keratan sulphate ranging from 0-5 to 4-0 [tg were added to 100 pt1 aliquots of inflammatory and non-inflammatory synovial fluid to investigate the extent to which keratan sulphate is recovered in the assay. More than 98% recovery was noted in both types of synovial fluid.
STATISTICAL METHODS
The effect ofpiroxicam on clinical and laboratory variables was measured by comparing the scores at the end of the piroxicam treatment phase (week 8) with the scores at the end of the first placebo phase (week 4). A paired t test (or signed rank sum test for paracetamol consumption) was used to test the significance of mean differences observed. Similarly the effect of stopping treatment was determined by comparing the week 12 scores with those at week 8.
Results
Twenty one patients (13 women, eight men) were enrolled in the study and 19 (11 women, eight men) completed the treatment course. One patient withdrew owing to oedema and another owing to purpura. These reactions resolved completely when treatment with piroxicam was stopped. The median age of the 19 patients completing the study was 70 years (range 52-81 years). Figure 1 shows the results for pain score, range of joint movement, and functional index. The mean change for these variables is shown in the table. Treatment with piroxicam was accompanied by a statistically significant decrease in pain score (p<0 05) and a significant improvement in the range of joint movement (p<0-01) and functional index (p<0 02). Lower paracetamol consumption was also observed during treatment with piroxicam (p<005, data not shown). Cross over to the placebo at the end of the period of treatment with piroxicam was accompanied by a significant deterioration in pain score (p<0002) and functional index (p<0-01) after a further four weeks. A trend towards a reduced range of movement was also observed during the the second placebo phase. Interestingly, deterioration in the pain score and functional index was not apparent until four weeks after piroxicam was withdrawn (see fig 1) . These sustained effects may be due to the long half life of the drug. Figure 2 shows the mean volume of synovial fluid aspirated at each time point during the study, together with the keratan sulphate concentrations and the total amount of keratan Time (weeks) Figure 2 (22) .tg/ml after receiving piroxicam for four weeks to 121 (10) ,ug/ml eight weeks after stopping treatment with the drug. Taken together these observations indicate that treatment with piroxicam lowers the keratan sulphate concentrations in synovial fluid from patients with osteoarthritis and suggest that this reduction continues after stopping treatment with the drug for up to eight weeks. The total amount of keratan sulphate in the joint cavity also declined significantly during treatment with piroxicam (p<005; fig  2) . A moderate increase in the total keratan sulphate concentration was observed during the second placebo phase, but this was not significant. It should be noted that aspirate volumes, keratan sulphate concentrations, and total keratan sulphate values were only available in subsets of the total group of patients (as shown in the table) due to some unsuccessful aspirations, the occasional retrieval of indeterminate volumes occupying only the dead space in the syringe, and contamination of some samples with blood.
Discussion
These results confirm the clinical efficacy of piroxicam in osteoarthritis and show that it does affect cartilage proteoglycan metabolism. 5 The proteoglycans in articular cartilage are composed of a core protein to which sulphated glycosaminoglycans are attached. 16 
